Delivery Order SPE2DR25D3101-SPE2DR26F5M63
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Medroxyprogesterone 150 mg/ml, a hormone treatment medication. This firm fixed-price delivery order, valued at $2,343.72, represents a non-competitive set-aside contract and is scheduled for ultimate completion by July 18, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/mL, a hormone treatment medication, valued at $7,627.72 under a firm fixed price contract. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 1, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,649.15 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/mL, a hormone-based pharmaceutical product. This non-competitive delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, utilizes firm fixed-price pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a $1,253.23 delivery order to AmerisourceBergen Drug Corp for Medroxyprogesterone 150 mg/mL, a hormone treatment medication. This non-set-aside, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and is classified as a firm fixed price delivery order. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a $1,003.18 delivery order to AmerisourceBergen Drug Corp for medroxyprogesterone on September 13, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside procurement executed under the company's existing contract vehicle. The work will be performed at the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $1,562.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on March 11, 2025, for the supply of Medroxyprogesterone 150 mg/ml with an ultimate completion date of March 12, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,839.57 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/ml. This competitive award, issued on September 4, 2025, carries a firm fixed price structure with performance completion targeted for September 5, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,495.01 to AmerisourceBergen Drug Corp for Medroxyprogesterone 150 mg/mL, a progestin medication used in hormone replacement therapy and contraceptive applications. The contract, issued on September 16, 2025, with an ultimate completion date of September 17, 2025, carries a firm fixed price and represents a non-competitive delivery order. Performance will be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Medroxyprogesterone 150 mg/ml, a synthetic progestin medication used for contraception and hormone therapy. This firm fixed-price delivery order, valued at $1,711.22, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026. The delivery is...
- The Defense Logistics Agency awarded a delivery order valued at $3,123.41 to AmerisourceBergen Drug Corp for the supply of Medroxyprogesterone 150 mg/mL, a synthetic progestin used in hormone therapy and contraceptive applications. This firm fixed-price contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical. The contract...
- SPE2DR25D3101Indefinite Delivery Contract
- SPE2DR25D3101-SPE2DR26F5M63Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Medroxyprogesterone 150 mg/ml, a hormone treatment pharmaceutical, on November 14, 2025. This firm fixed-price delivery order, valued at $3,153.62, is scheduled for completion by November 17, 2025 and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating the contract was competitively awarded through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive contract history with the DLA demonstrates its capability to fulfill diverse medical supply requirements across multiple therapeutic domains on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 11/14/25 |